title: The clonal distribution and diversity of extraintestinal Escherichia coli isolates vary according to patient characteristics.
abstract: The clonal distribution of Escherichia coli across an unselected population in the current era of widespread antimicrobial resistance is incompletely defined. In this study, we used a newly described clonal typing strategy based on sequencing of fumC and fimH (i.e., CH typing) to infer multilocus sequence types (STs) for 299 consecutive, nonduplicate extraintestinal E. coli isolates from all cultures submitted to Olmsted County, MN, laboratories in February and March 2011 and then compared STs with epidemiological data. Forty-seven different STs were identified, most commonly ST131 (27%), ST95 (11%), ST73 (8%), ST127 (6%), and ST69 (5%). Isolates from these five STs comprised two-thirds of health care-associated (HA) isolates but only half of community-associated (CA) isolates. ST131 was represented overwhelmingly (88%) by a single recently expanded H30 subclone, which was the most extensively antimicrobial-resistant subclone overall and was especially predominant in HA infections and among adults >50 years old. In contrast, among patients 11 to 50 years old, ST69, -95, and -73 were more common. Because of the preponderance of the H30 subclone of ST131, ST diversity was lower among HA than CA isolates, and among antimicrobial-resistant than antimicrobial-susceptible isolates, which otherwise had similar ST distributions. In conclusion, in this U.S. Midwest region, the distribution and diversity of STs among extraintestinal E. coli clinical isolates vary by patient age, type of infection, and resistance phenotype. ST131 predominates among young children and the elderly, HA infections, and antimicrobial-resistant isolates, whereas other well-known pathogenic lineages are more common among adolescents and young adults, CA infections, and antimicrobial-susceptible isolates.
authors.affiliation: Mayo Clinic, Rochester, Minnesota, USA.
authors.forename: Ritu
authors.initials: R
authors.lastname: Banerjee
authors.forename: Brian
authors.initials: B
authors.lastname: Johnston
authors.forename: Christine
authors.initials: C
authors.lastname: Lohse
authors.forename: Sujay
authors.initials: S
authors.lastname: Chattopadhyay
authors.forename: Veronika
authors.initials: V
authors.lastname: Tchesnokova
authors.forename: Evgeni V
authors.initials: EV
authors.lastname: Sokurenko
authors.forename: James R
authors.initials: JR
authors.lastname: Johnson
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D002999:Clone Cells; D004269:DNA, Bacterial / Q000235:genetics*; D024881:Drug Resistance, Bacterial; D004926:Escherichia coli / Q000145:classification* / Q000187:drug effects / Q000235:genetics* / Q000302:isolation & purification; D004927:Escherichia coli Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology; D005260:Female; D014644:Genetic Variation; D058507:Host Specificity; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D008910:Minnesota / Q000453:epidemiology; D058885:Multilocus Sequence Typing
chemical_list: D000900:Anti-Bacterial Agents; D004269:DNA, Bacterial
references.citation: J Clin Microbiol. 2009 Jun;47(6):1857-62
references.pmid: 19339467
references.citation: J Infect Dis. 2013 Mar 15;207(6):919-28
references.pmid: 23288927
references.citation: Lancet. 2002 Jun 29;359(9325):2249-51
references.pmid: 12103291
references.citation: J Antimicrob Chemother. 2009 Jun;63(6):1135-41
references.pmid: 19351692
references.citation: Clin Infect Dis. 2010 Aug 1;51(3):286-94
references.pmid: 20572763
references.citation: Emerg Infect Dis. 2008 Oct;14(10):1575-83
references.pmid: 18826822
references.citation: Antimicrob Agents Chemother. 2012 May;56(5):2364-70
references.pmid: 22354301
references.citation: J Antimicrob Chemother. 2012 Feb;67(2):346-56
references.pmid: 22028202
references.citation: Antimicrob Agents Chemother. 2001 May;45(5):1402-6
references.pmid: 11302802
references.citation: Euro Surveill. 2008 Nov 20;13(47):
references.pmid: 19021958
references.citation: J Antimicrob Chemother. 2011 Nov;66(11):2501-8
references.pmid: 21862477
references.citation: Int J Antimicrob Agents. 2010 Jul;36(1):19-23
references.pmid: 20359869
references.citation: J Antimicrob Chemother. 2008 Feb;61(2):273-81
references.pmid: 18077311
references.citation: J Mol Evol. 2007 Feb;64(2):204-14
references.pmid: 17177088
references.citation: N Engl J Med. 2001 Oct 4;345(14):1007-13
references.pmid: 11586952
references.citation: J Clin Microbiol. 2012 Sep;50(9):2974-81
references.pmid: 22760036
references.citation: Appl Environ Microbiol. 2012 Mar;78(5):1353-60
references.pmid: 22226951
references.citation: Appl Environ Microbiol. 2000 Oct;66(10):4555-8
references.pmid: 11010916
references.citation: J Med Microbiol. 1990 Sep;33(1):23-7
references.pmid: 1700126
references.citation: J Clin Microbiol. 2008 Aug;46(8):2605-12
references.pmid: 18579721
references.citation: Antimicrob Agents Chemother. 2009 Jul;53(7):2733-9
references.pmid: 19398649
references.citation: Antimicrob Agents Chemother. 2013 Jan;57(1):490-7
references.pmid: 23147723
references.citation: J Antimicrob Chemother. 2010 Sep;65(9):1936-8
references.pmid: 20570998
references.citation: Infect Control Hosp Epidemiol. 2013 Apr;34(4):361-9
references.pmid: 23466908